Quince Therapeutics Inc (QNCX) Stock Analysis
Verdict: AVOID
Survival depends entirely on a dilutive $187M private placement to pivot away from a failed bone pipeline into pulmonary hypertension.
Investment score: 28/100
Analysis as of
Is Quince Therapeutics Inc stock worth reviewing? AI model thesis
Quince is a high-risk micro-cap in the midst of a desperate strategic pivot. Despite positive Phase 2a data for LAM-001, the financial structure (negative equity, high burn, massive impending dilution) makes the common stock a high-probability loser for non-institutional holders.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Quince Therapeutics Inc opportunities and risks
What speaks for QNCX
- LAM-001 Phase 2a Success
What speaks against QNCX
- Massive Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| QNCX | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -647.4% |
| CRIS | n/a | 0.9x | 0.9x | 99.4% | -299.7% | -438.6% |
| HCWB | n/a | 0.9x | n/a | 99.2% | -24.7% | -190.0% |
| APUS | n/a | 0.0x | n/a | 0.0% | 0.0% | -476.2% |
| XCUR | n/a | 0.0x | n/a | 0.0% | 0.0% | -47.8% |
| ACUT | n/a | 0.0x | 0.0x | 0.0% | 0.0% | — |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -314.3% |
Frequently asked questions about Quince Therapeutics Inc (QNCX)
Is QNCX stock a good investment?
The cached TradeMates AI model rates Quince Therapeutics Inc as AVOID with an investment score of 28/100. Quince is a high-risk micro-cap in the midst of a desperate strategic pivot. Despite positive Phase 2a data for LAM-001, the financial structure (negative equity, high burn, massive impending dilution) makes the common stock a high-probability loser for non-institutional holders. This is algorithmic model output, not personal investment advice.
Is QNCX stock a buy?
The TradeMates model verdict for QNCX is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.